1. Home
  2. AEI vs ELTX Comparison

AEI vs ELTX Comparison

Compare AEI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

SELL

Current Price

$0.47

Market Cap

54.8M

Sector

Real Estate

ML Signal

SELL

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

SELL

Current Price

$1.41

Market Cap

45.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AEI
ELTX
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.8M
45.6M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
AEI
ELTX
Price
$0.47
$1.41
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $13.00
AVG Volume (30 Days)
143.6K
★ 303.3K
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.29
EPS
★ N/A
N/A
Revenue
★ $16,238,200.00
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.38
$1.25
52 Week High
$3.98
$16.00

Technical Indicators

Market Signals
Indicator
AEI
ELTX
Relative Strength Index (RSI) 37.50 36.79
Support Level N/A $1.25
Resistance Level $0.74 $1.98
Average True Range (ATR) 0.07 0.19
MACD 0.01 -0.00
Stochastic Oscillator 42.60 25.00

Price Performance

Historical Comparison
AEI
ELTX

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: Real Estate, Digital Transformation Technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: